within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX21_Naxitamab;
model Naxitamab 
   extends Pharmacolibrary.Drugs.ATC.L.L01FX21;

  annotation(Documentation(
    info ="<html><body><p>Naxitamab is a humanized monoclonal antibody that targets the disialoganglioside GD2. It is indicated for the treatment of relapsed or refractory high-risk neuroblastoma in pediatric and adult patients and is approved by the FDA for this use. Its main therapeutic activity comes from immune-mediated killing of GD2-expressing tumor cells.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for intravenous administration in pediatric patients with high-risk neuroblastoma, as no direct published PK study was found.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Naxitamab;
